Researchers from Shenzhen Winkey Technology, P&G Singapore Innovation Center and Nanyang Technological University introduced CH-9, a peptide-drug conjugate ingredient that links a collagen-mimicking hexapeptide with caffeic acid, featuring improved stability and skin delivery. The team developed the hybrid molecule using solid-phase peptide synthesis to achieve high purity and a single conjugate structure.
Laboratory tests showed CH-9 offered antioxidant activity in DPPH and ORAC assays and restored collagen types I, III and IV in UVB-challenged keratinocytes and fibroblasts. Molecular dynamics and Raman spectroscopy indicated deeper stratum corneum penetration within 30 minutes, while the conjugate resisted oxidation that typically discolors caffeic acid.
A 28-day double-blind trial with 96 women found CH-9 doubled improvements in elasticity and firmness versus the parent peptide, suggesting PDC technology can deliver multifunctional, stable anti-photoaging actives for advanced topical formulations.
Peptide-Drug Conjugate Actives
Shenzhen Winkey Unveiled CH-9 Caffeoyl Hexapeptide-9
Trend Themes
-
Peptide-drug Conjugate Actives — The emergence of single-conjugate PDCs that combine peptide scaffolds with small-molecule actives presents opportunities for multifunctional, oxidation-resistant topical ingredients with enhanced bioactivity.
-
Collagen-mimetic Peptides — High-purity collagen-mimicking hexapeptides that restore multiple collagen types suggest new routes for targeted anti-photoaging formulations with biomimetic repair mechanisms.
-
Rapid Stratum Corneum Penetration — Molecules demonstrating measurable skin-layer penetration within minutes indicate potential for fast-acting dermal delivery systems and differentiated sensory profiles in topical products.
Industry Implications
-
Skincare and Cosmetics — Clinically validated PDC actives that double improvements in elasticity and firmness open space for premium cosmeceutical lines emphasizing measurable anti-aging performance.
-
Pharmaceutical Topicals — Stable conjugates that resist oxidation and enhance dermal delivery create potential for prescription-strength or OTC topical therapeutics with improved efficacy and stability.
-
Contract Synthesis and Manufacturing — Demand for high-purity solid-phase peptide synthesis and single-conjugate control points toward specialized manufacturing services and quality-driven supply-chain partnerships.